Phase 1 Study of KHK2898 in Subjects With Advanced Solid Tumors
Status:
Terminated
Trial end date:
2015-05-01
Target enrollment:
Participant gender:
Summary
This is a two-part, Phase 1 open label, single-center, dose escalation study of KHK2898 as
monotherapy in subjects with advanced solid tumors who no longer respond to standard therapy
or for whom no standard therapy is available.
Phase:
Phase 1
Details
Lead Sponsor:
Kyowa Hakko Kirin Company, Limited Kyowa Kirin Co., Ltd.